Cargando…
1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine
Autores principales: | Thomas, S.J., Perez, J.L., Lockhart, S.P., Hariharan, S., Kitchin, N., Bailey, R., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., Xu, X., Dychter, S.S., Lu, C., Gentile, T., Gruber, W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454396/ http://dx.doi.org/10.1016/j.annonc.2021.08.1551 |
Ejemplares similares
-
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
por: Thomas, Stephen J., et al.
Publicado: (2022) -
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022) -
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021) -
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023) -
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
por: Haranaka, Miwa, et al.
Publicado: (2021)